Abstracts tagged "dermatomyositis and malignancy"

Abstract Number: 280 • 2016 ACR/ARHP Annual Meeting
Increased Expression of TIF-1 Gamma in Duodenal Adenocarcinoma from a Patient with p155/140 Dermatomyositis: A Causal Relationship?
Marcello DiStasio¹ and George Stojan², ¹Pathology, Beth Israel Deaconess Medical Center, Boston, MA, ²Division of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Increased expression of TIF-1 gamma in duodenal adenocarcinoma from a patient with p155/140 dermatomyositis: a causal relationship? Background/Purpose: poor prognosis and worse survival in breast…
Abstract Number: 2312 • 2016 ACR/ARHP Annual Meeting
Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis
Paulius Venalis¹, Sandra Selickaja^2,3, Karin Lundberg⁴, Rita Rugiene^5,6 and Ingrid E. Lundberg⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Vilnius University, Center of Rheumatology;, Vilnius, Lithuania, ³State Research Institute for Innovative Medicine, Vilnius, Lithuania, ⁴Rheumatology Unit, Department, Karolinska Institute, Stockholm, Sweden, ⁵Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ⁶State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ⁷Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: An association between cancer and dermatomyositis (DM), referred to as cancer-associated myositis, is well recognized and clinically important. The overall cancer risk is up…
Abstract Number: 2367 • 2015 ACR/ARHP Annual Meeting
Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Shinji Sato¹, Takayoshi Kurabayashi¹, Sho Sasaki², Yasushi Koyama², Shinichi Nogi³, Naofumi Chinen¹, Chiho Yamada¹ and Yasuo Suzuki¹, ¹Internal Medicine/ Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Internal Medicine/Rheumatology, Tokai University School of Medicine, Isehara, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-CADM-140/ Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].